MeVis Medical Solutions AG (M3V) Fair Value & Analysis
Healthcare · DE · Market cap €44.0M
Fair value as of: Jul 15, 2026
From 24 valuation models · updated 26 days ago
Share price −2.5% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from €20.23 (bear) to €32.32 (bull), base €24.48. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 73/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.
How to read this chart
60‑month range €20.71 – €33.21 · fair‑value band €20.23 – €32.32 · the €23.60 price screens below the €24.48 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 15, 2026.
Analysis
MeVis Medical Solutions AG (M3V) currently trades at €23.60, while our model-based Fair Value estimate is €24.48, implying the stock looks roughly 3.7% fairly valued today. The Quality Score stands at 73/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, MeVis Medical Solutions AG generated revenue of €15.5M at a net margin of 8.9%. Revenue declined 6.8% year over year. It earns a return on equity of 7.8%. The balance sheet holds a net cash position of €6.5M. Fundamentals as of Jul 15, 2026
Our scenario range runs from €20.23 (bear case) to €32.32 (bull case); at €23.60, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 9% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at 4%, M3V screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (€28.90) versus Asset-Based (€6.56). Highest evidence: Residual Income (76).
Notify me when M3V reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 76 · Market factors (momentum, volatility) 55
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
MeVis Medical Solutions AG develops software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe.
Full company description
MeVis Medical Solutions AG develops software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company provides image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological diseases. It also offers X-ray based radiography procedures, including computed tomography, mammography/digital tomosynthesis, magnetic resonance imaging, and digital sonography; as well as provides services in the field of software programming for medical technology companies, which comprise provision of software developers, product and project managers, application specialists, and test engineers. In addition, the company provides three-dimensional technical visualizations; and interactive online training to enhance the diagnostic skills of clinicians; and internet-based special applications in teleradiology. The company was founded in 1997 and is based in Bremen, Germany. MeVis Medical Solutions AG is a subsidiary of Varex Imaging Corporation.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
MeVis Medical Solutions AG reported revenue of €16.1M in FY2025 versus €16.2M in FY2021, a compound −0.2%/yr. Reported net income was €3.2M in FY2025, compounding −8.6%/yr from FY2021.
of which total revenue +1.2 pp · buybacks/dilution −0.2 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch M3V: get an alert when its fair value changes →
Peer Group
Health Information Services · 126 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $190.12 | $95.12 | -50% |
| Pro Medicus Limited PME | A$194.84 | A$23.74 | -88% |
| BrightSpring Health Services, Inc BTSG | $68.16 | $21.31 | -69% |
| HealthEquity, Inc HQY | $97.67 | $56.63 | -42% |
| Hinge Health, Inc HNGE | $88.80 | $24.03 | -73% |
| 10x Genomics, Inc TXG | $45.75 | $17.18 | -62% |
| Waystar Holding WAY | $22.69 | $12.86 | -43% |
| Doximity, Inc DOCS | $22.21 | $17.18 | -23% |
| Privia Health Group PRVA | $28.10 | $5.30 | -81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,846 | ₹860.28 | -53% |
Compare MeVis Medical Solutions AG with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is MeVis Medical Solutions AG (M3V) overvalued or undervalued?
What is the fair value of M3V?
What is the quality score of M3V?
What is the revenue of MeVis Medical Solutions AG (M3V)?
What is the net profit margin of M3V?
Does MeVis Medical Solutions AG pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track MeVis Medical Solutions AG and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.